• Who we are

    Founded in Paris in 1920, Gide is a leading international law firm with 12 offices spread throughout the world.

    Lancer la video dans une nouvelle page

  • Our team

    550 lawyers, including some 100 partners.

    • See all lawyers
    • Search in the directory
      select arrows
      select arrows
      select arrows
      select arrows
    • Scientific council

  • News & insights

    Gide communicates actively and regularly in the press and via its newsletters.

  • Careers

    Join Gide and become part of one of the few truly international French law firms.

    Apply onlineCurrent vacancies

You are here

Home > News & Insights > Gide, counsel to Inserm Transfert Initiative and Versant Ventures on their investment in AAVLife

News & Insights

Gide, counsel to Inserm Transfert Initiative and Versant Ventures on their investment in AAVLife

21 May 2014

Deals | France - M&A

Gide has advised Inserm Transfert Initiative and Versant Ventures on their 12-million-dollar investment in the share capital of AAVLife, a company specialising in gene therapy for rare diseases, in particular the heart dysfunction associated with Friedreich’s Ataxia.  

Legal counsel to Inserm Transfert Initiative and Versant Ventures:
Gide, Karen Noël (partner) and Pierre-Emmanuel Sirgue.

Legal counsel to AAVLife:
King & Wood Mallesons SJ Berwin, Pierre-Louis Périn (partner) and Rémi Pagès.

 

 

Top
© Gide 2024